Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
US pharma major AbbVie (NYSE: ABBV) has filed a lawsuit seeking to narrow the definition of a “340B patient,” opening a new ...
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, ...
The five richest physicians in the world built fortunes spanning biotech breakthroughs and healthcare empires, but their “self-made” status varies widely, from billionaire founders who started with ...
The FDA’s former top drug regulator Richard Pazdur, M.D., has lamented the loss of expert voices at the agency. | Asked by ...
US phase 3 ASTRA (NCT07368959) will enroll across ~12 sites, randomizing patients to a single intracameral administration of ...
He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...
Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...
The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary ...
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, ...
Anxiety drug Xanax is under recall. Here’s what to know - The recalled pills may not break down in the body and release the ...
In the latest meeting minutes released by the US Food and Drug Administration (FDA), the agency noted that significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results